Reproduction, movements, and population dynamics of the southern kingfish, Menticirrhus americanus, in the northwestern Gulf of Mexico

Menlicirrhus americanus in the northwestern Gulf of Mexico mature at 150-220 mm TL and 12-14 months of age, with males maturing when 10-40 mm smaller than females. Spawning occurs within a broad period from February through November with two discrete peaks which coincide with the periodicity of downcoast alongshore currents (towards Mexico) in spring and fall. This species occurs at depths of less than 5 to 27 m, being most abundant at 5 m or shallower. Young-of-the-year recruit primarily at 5-9 m or shallower and gradually expand their bathymetric range. Age determination by length frequency is feasible in M. americanus but not as simple as in species that spawn in one major period of the year. Only one or two spawned groups normally predominated at anyone time and no more than three co-occurred with few possible exceptions. Observed mean sizes were 138 mm TL at 6 months, and 192 and 272 mm at ages I and II, respectively. Typical maximum size was 296-308 mm and typical maximum age is probably 2-3 years. The largest fISh captured were 392 and 455 mm. Observed sex ratio was 1.2 females to 1 male. Weight, girth, and length-length regressions are presented.(PDF file contains 27 pages.

Age, Growth, and Mortality of Atlantic Croaker, Micropogonias undulatus, in the Chesapeake Bay Region, With a Discussion of Apparent Geographic Changes in Population Dynamics

Atlantic croaker, Micropogonias undulatus, collected from commercial catches in Chesapeake Bay and in Virginia and North Carolina coastal waters during 1988-1991 (n=1,967) were aged from transverse otolith sections. Ages 1-8 were recorded, but eight-year-old fish were rare. Marginal increment analysis showed that for ages 1-7, annuli are formed once a year during the period April-May. Otolith age readings were precise: \u3e99% agreement within and between readers. Observed lengths-at-age were highly variable and growth rate decreased after the first year. Despite the high variability in sizes-at-age, observed lengths for ages 1-7 fit the von Bertalanffy growth model (r2=0.99; n=753) well. No differences in growth were found between sexes. Total annual instantaneous mortality (Z) estimated from maximum age and from a catch curve of Chesapeake Bay commercial catches ranged from 0.55 to 0.63. Our results do not indicate the existence of a group of larger, older Atlantic croaker in Chesapeake Bay compared with more southern waters and suggest that the hypothesis of a basically different population dynamics pattern for this species north and south of Cape Hatteras, North Carolina, should be reevaluated

PDE 7 Inhibitors: New Potential Drugs for the Therapy of Spinal Cord Injury

BACKGROUND: Primary traumatic mechanical injury to the spinal cord (SCI) causes the death of a number of neurons that to date can neither be recovered nor regenerated. During the last years our group has been involved in the design, synthesis and evaluation of PDE7 inhibitors as new innovative drugs for several neurological disorders. Our working hypothesis is based on two different facts. Firstly, neuroinflammation is modulated by cAMP levels, thus the key role for phosphodiesterases (PDEs), which hydrolyze cAMP, is undoubtedly demonstrated. On the other hand, PDE7 is expressed simultaneously on leukocytes and on the brain, highlighting the potential crucial role of PDE7 as drug target for neuroinflammation. METHODOLOGY/PRINCIPAL FINDINGS: Here we present two chemically diverse families of PDE7 inhibitors, designed using computational techniques such as virtual screening and neuronal networks. We report their biological profile and their efficacy in an experimental SCI model induced by the application of vascular clips (force of 24 g) to the dura via a four-level T5-T8 laminectomy. We have selected two candidates, namely S14 and VP1.15, as PDE7 inhibitors. These compounds increase cAMP production both in macrophage and neuronal cell lines. Regarding drug-like properties, compounds were able to cross the blood brain barrier using parallel artificial membranes (PAMPA) methodology. SCI in mice resulted in severe trauma characterized by edema, neutrophil infiltration, and production of a range of inflammatory mediators, tissue damage, and apoptosis. Treatment of the mice with S14 and VP1.15, two PDE7 inhibitors, significantly reduced the degree of spinal cord inflammation, tissue injury (histological score), and TNF-α, IL-6, COX-2 and iNOS expression. CONCLUSIONS/SIGNIFICANCE: All these data together led us to propose PDE7 inhibitors, and specifically S14 and VP1.15, as potential drug candidates to be further studied for the treatment of SCI

Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors

Stiffness is a biophysical property of the extracellular matrix that modulates cellular functions, including proliferation, invasion, and differentiation, and it also may affect therapeutic responses. Therapeutic durability in cancer treatments remains a problem for both chemotherapies and pathway-targeted drugs, but the reasons for this are not well understood. Tumor progression is accompanied by changes in the biophysical properties of the tissue, and we asked whether matrix rigidity modulated the sensitive versus resistant states in HER2-amplified breast cancer cell responses to the HER2-targeted kinase inhibitor lapatinib. The antiproliferative effect of lapatinib was inversely proportional to the elastic modulus of the adhesive substrata. Down-regulation of the mechanosensitive transcription coactivators YAP and TAZ, either by siRNA or with the small-molecule YAP/TEAD inhibitor verteporfin, eliminated modulus-dependent lapatinib resistance. Reduction of YAP in vivo in mice also slowed the growth of implanted HER2-amplified tumors, showing a trend of increasing sensitivity to lapatinib as YAP decreased. Thus we address the role of stiffness in resistance to and efficacy of a HER2 pathway–targeted therapeutic via the mechanotransduction arm of the Hippo pathway